Synthesis and biological screening of new 5-oximidazoline molecules possessing sulfadiazine moiety for cancer treatment.
1/5 보강
[AIM] To synthesize a series of new 5-oximidazoline-sulfadiazine hybrids and assess their anti-cancer ( and ) activities.
APA
Alqahtani AS, Alzahrani AYA, et al. (2026). Synthesis and biological screening of new 5-oximidazoline molecules possessing sulfadiazine moiety for cancer treatment.. Future medicinal chemistry, 18(5), 513-524. https://doi.org/10.1080/17568919.2026.2620556
MLA
Alqahtani AS, et al.. "Synthesis and biological screening of new 5-oximidazoline molecules possessing sulfadiazine moiety for cancer treatment.." Future medicinal chemistry, vol. 18, no. 5, 2026, pp. 513-524.
PMID
41631716
Abstract
[AIM] To synthesize a series of new 5-oximidazoline-sulfadiazine hybrids and assess their anti-cancer ( and ) activities.
[MATERIALS AND METHODS] The antiproliferative activity was assessed against the hepatocellular carcinoma (HepG2) cell line. Moreover, the enzymatic inhibitory activity against EGFR-TK for all the synthesized members was then assessed. In addition, cell cycle analysis, apoptosis induction, and toxicity assessment of the most active analog were also conducted.
[RESULTS] The analog with 3,4,5-trimethoxybenzylidene in the 5-oximidazoline ring revealed good cytotoxicity and selectivity against the HepG2 cancer cells relative to the normal cells, especially compounds and . Besides, toxicity assessment revealed that compound increased life-span prolongation of the EAC-bearing mice group and reduced the volume and EAC cells count in animal models.
[CONCLUSION] Accordingly, the afforded 5-oximidazoline-sulfadiazine hybrids represent promising lead candidates for further optimization to obtain promising anticancer agents.
[MATERIALS AND METHODS] The antiproliferative activity was assessed against the hepatocellular carcinoma (HepG2) cell line. Moreover, the enzymatic inhibitory activity against EGFR-TK for all the synthesized members was then assessed. In addition, cell cycle analysis, apoptosis induction, and toxicity assessment of the most active analog were also conducted.
[RESULTS] The analog with 3,4,5-trimethoxybenzylidene in the 5-oximidazoline ring revealed good cytotoxicity and selectivity against the HepG2 cancer cells relative to the normal cells, especially compounds and . Besides, toxicity assessment revealed that compound increased life-span prolongation of the EAC-bearing mice group and reduced the volume and EAC cells count in animal models.
[CONCLUSION] Accordingly, the afforded 5-oximidazoline-sulfadiazine hybrids represent promising lead candidates for further optimization to obtain promising anticancer agents.